Author:
M.E. Sergienko
Road Clinical Hospital, Chelyabinsk
Author:
M.E. Sergienko
Road Clinical Hospital, Chelyabinsk
Place of publication:
PHARMATEKA No. 19 - 2012
Abstract:
A study involving 34 patients examined the efficacy of Mexidol in the treatment of asthenovegetative disorders in individuals who had suffered mild traumatic brain injury (MTBI) and concussion. The use of Mexidol as part of a comprehensive treatment regimen for these disorders improved treatment outcomes compared to a control group of patients who did not receive Mexidol. It was noted that the drug should be administered earlier after injury. A clear therapeutic effect was achieved with Mexidol administered at a daily dose of 375 mg in tablet form for 28–30 days during the acute and intermediate periods of MTBI. No side effects or complications were observed in either group. It is concluded that Mexidol can be used in the comprehensive treatment of MTBI, concussion, and the correction of post-concussion syndrome.
THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.
Source of photos and images Shutterstock.com